Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Textiles Press Releases.
Press releases published on May 7, 2025
Fluence Energy, Inc. Reports Second Quarter 2025 Results; Lowers Full Year 2025 Guidance, Citing Decisions to Pause Certain U.S. Projects Due to Tariff Uncertainty
GlobeNewswire
·
May 7, 2025
ARLINGTON, Va., May 07, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its …
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
GlobeNewswire
·
May 7, 2025
BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management …
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
GlobeNewswire
·
May 7, 2025
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration …
New Toll Brothers Copperhaven Model Home Opens in West Jordan, Utah
GlobeNewswire
·
May 7, 2025
WEST JORDAN, Utah, May 07, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL) the nation’s leading builder of luxury homes, today announced the grand opening of the new model home at its Copperhaven by Toll Brothers community located in the heart of …
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
GlobeNewswire
·
May 7, 2025
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment …
FormFactor Announces Participation at Upcoming Conferences
GlobeNewswire
·
May 7, 2025
LIVERMORE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) is pleased to announce its participation in the following investor conferences: B. Riley 25th Annual Investor Conference Location: The Ritz-Carlton, Marina del Rey Date: …
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose- …
OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System
GlobeNewswire
·
May 7, 2025
WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and …
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM …
Introducing Sunrun Flex, a Superior Solar and Storage Solution for Consumers
GlobeNewswire
·
May 7, 2025
SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), the nation's leading provider of clean energy as a subscription service, today introduced Sunrun Flex™, the first solar and battery storage solution designed to adapt to customers' …
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund …
Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025
GlobeNewswire
·
May 7, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter …
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
GlobeNewswire
·
May 7, 2025
– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML …
Avis Budget Group Reports First Quarter Results
GlobeNewswire
·
May 7, 2025
PARSIPPANY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for first quarter 2025 today. We ended the quarter with revenues of $2.4 billion, net loss of $505 million, and an Adjusted EBITDA1 loss of …
MYR Group Inc. to Attend Baird 2025 Global Consumer, Technology & Services Conference in June
GlobeNewswire
·
May 7, 2025
THORNTON, Colo., May 07, 2025 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial and industrial construction markets in the United …
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
GlobeNewswire
·
May 7, 2025
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s …
Cytokinetics to Hold Annual Meeting of Stockholders
GlobeNewswire
·
May 7, 2025
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 14, 2025 at 10:00 AM Pacific Time at the Company’s headquarters, …
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 7, 2025
Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 …
Photronics Announces Upcoming Investor Events
GlobeNewswire
·
May 7, 2025
BROOKFIELD, Conn., May 07, 2025 (GLOBE NEWSWIRE) -- Photronics, Inc. (Nasdaq:PLAB), a worldwide leader in photomask technologies and solutions, announced today its participation in the following upcoming financial conferences: Date: Thursday, May 29th …
Symbotic Reports Second Quarter Fiscal Year 2025 Results
GlobeNewswire
·
May 7, 2025
WILMINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the supply chain, announced financial results for its second quarter of fiscal year 2025, which ended on March 29, 2025. …